Trials / Completed
CompletedNCT00566735
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Razadyne | The starting dose of study medication is 4 mg twice a day |
| DRUG | Placebo | 4 mg, 2 times a day |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2007-12-04
- Last updated
- 2012-12-03
- Results posted
- 2012-12-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00566735. Inclusion in this directory is not an endorsement.